Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 4:13:1046818.
doi: 10.3389/fphar.2022.1046818. eCollection 2022.

Indoleamine 2, 3-dioxygenase 1 inhibitory compounds from natural sources

Affiliations
Review

Indoleamine 2, 3-dioxygenase 1 inhibitory compounds from natural sources

Ying Tan et al. Front Pharmacol. .

Abstract

L-tryptophan metabolism is involved in the regulation of many important physiological processes, such as, immune response, inflammation, and neuronal function. Indoleamine 2, 3-dioxygenase 1 (IDO1) is a key enzyme that catalyzes the first rate-limiting step of tryptophan conversion to kynurenine. Thus, inhibiting IDO1 may have therapeutic benefits for various diseases, such as, cancer, autoimmune disease, and depression. In the search for potent IDO1 inhibitors, natural quinones were the first reported IDO1 inhibitors with potent inhibitory activity. Subsequently, natural compounds with diverse structures have been found to have anti-IDO1 inhibitory activity. In this review, we provide a summary of these natural IDO1 inhibitors, which are classified as quinones, polyphenols, alkaloids and others. The overview of in vitro IDO1 inhibitory activity of natural compounds will help medicinal chemists to understand the mode of action and medical benefits of them. The scaffolds of these natural compounds can also be used for further optimization of potent IDO1 inhibitors.

Keywords: IDO1 inhibitors; indoleamine 2, 3-dioxygenase 1; kynurenine; natural compounds; tryptophan.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Metabolic pathway of L-Tryptophan.
FIGURE 2
FIGURE 2
Crystal structure shows the active site of IDO1 with the binding of the ligand of PI.
FIGURE 3
FIGURE 3
Mechanism of IDO1-mediated tumor immune escape.
FIGURE 4
FIGURE 4
Structures of natural 1, 2- and 1, 4-quinones with their IDO1 inhibitory activity.
FIGURE 5
FIGURE 5
Structures of natural polyphenols with their IDO1 inhibitory activity.
FIGURE 6
FIGURE 6
Structures of natural alkaloids with their IDO1 inhibitory activity.
FIGURE 7
FIGURE 7
Structure of NSC401366.

Similar articles

Cited by

References

    1. Albini E., Rosini V., Gargaro M., Mondanelli G., Belladonna M. L., Pallotta M. T., et al. (2017). Distinct roles of immunoreceptor tyrosine-based motifs in immunosuppressive indoleamine 2, 3-dioxygenase 1. J. Cell. Mol. Med. 21 (1), 165–176. 10.1111/jcmm.12954 - DOI - PMC - PubMed
    1. Alves de Souza T. M., Fernandes-Santos C., Araujo da Paixao de Oliveira J., Tome L. C. T., Fiestas-Solorzano V. E., Nunes P. C. G., et al. (2022). Increased indoleamine 2, 3-dioxygenase 1 (Ido-1) activity and inflammatory responses during chikungunya virus infection. Pathogens 11 (4), 444. 10.3390/pathogens11040444 - DOI - PMC - PubMed
    1. Arneth B. (2019). Tumor microenvironment. Med. Kaunas. Lith. 56 (1), E15. 10.3390/medicina56010015 - DOI - PMC - PubMed
    1. Austin C. J., Kahlert J., Issa F., Reed J. H., Smith J. R., Ioppolo J. A., et al. (2014). The first indoleamine-2, 3-dioxygenase-1 (Ido1) inhibitors containing carborane, Dalton Trans., 43, 10719–10724. 10.1039/c4dt00444b - DOI - PubMed
    1. Badawy A. A., Morgan C. J. (1991). Effects of acute paroxetine administration on tryptophan metabolism and disposition in the rat. Br. J. Pharmacol. 102 (2), 429–433. 10.1111/j.1476-5381.1991.tb12190.x - DOI - PMC - PubMed